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Wambui Grace Gathirua-Mwangi 
Obesity and Obesity-Related Markers Associated with Breast and Colorectal 
Cancer Occurrence and Mortality 
Purpose: Obesity is a growing public health problem and the second most 
preventable cause of death in the US. Obesity has been linked as a risk factor for 
several cancers. However, there are limited studies that have examined the roles 
of metabolic syndrome (MetS) and C-reactive protein (CRP), as well as change 
in body composition from early adulthood to late adulthood on the risk of cancer. 
The overall objective of this dissertation was to determine the association of 
obesity and obesity-related markers with breast and colorectal cancer occurrence 
and mortality. 
Methods: Three datasets were used. The first study used 4,500 asymptomatic 
adults who were surveyed during a colorectal cancer screening study. The 
second study was based on the National Health and Nutrition Examination 
Survey (NHANES) 2005-2010. The dataset had 172 breast cancer survivors and 
2,000 women without breast cancer. The last manuscript resulted from the 
NHANES follow-up study (NHANES III). A total of 120 cancer deaths from breast 
and colorectal deaths were identified from 10,103 women aged 18 years or older.   
Results: Overall, obesity and obesity related markers were associated with 
breast and colorectal cancer occurrence and mortality. BMI change and WC 
change were positively associated with increased risk of advanced colorectal 
neoplasia (AN). WC measures (both static and dynamic) were generally a better 
predictor of AN compared to BMI. In the second study involving breast cancer 
vi 
survivors, neither MetS nor CRP were associated with having a breast cancer 
diagnosis. Also, none of the individual components of MetS (WC, Triglycerides, 
HDL, fasting blood glucose and blood pressure) were associated with a breast 
cancer diagnosis. In the last study, MetS was associated with increased risk of 
mortality from obesity-related cancers. In addition, all components of MetS, 
except dyslipidemia, were associated with increased risk of mortality for the 
obesity-related cancers.  
Conclusion:  Obesity expressed in terms of BMI and WC, or their change, MetS 
and CRP are important factors in regard to the occurrence, survivorship and 
mortality of breast and colorectal cancer. The results of this research underscore 
the importance of maintaining a healthy weight.  
 
 
Terrell W. Zollinger, DrPH, Co-chair 
Yiqing Song, MD, ScD, Co-chair 
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INTRODUCTION 
Obesity is a growing public health problem and the second most 
preventable cause of death in the US (1). Obesity occurs when there is chronic 
energy imbalance, that is, when energy consumption regularly exceeds energy 
needs over a long period of time.  According to the World Health Organization, in 
2014 more than 1.9 billion adults, 18 years and older, were overweight; of these 
over 600 million were obese (2, 3).  Developed countries were found to have the 
highest obesity prevalence; more than one third of adults in the US were 
estimated to be obese in 2012 (2, 4). Moreover, it was estimated that at the end 
of  2015, 41% of adults in the US were obese (5).  
There is growing evidence that obesity is a risk factor for many cancers 
(6). Epidemiological evidence indicates that obesity is associated with increased 
risk of the following cancers: endometrial, esophageal adenocarcinoma, 
colorectal and postmenopausal breast cancer (6). To understand the link 
between obesity and cancer, several aspects of obesity and how it links with 
cancer continue to be explored. Weight gain earlier in life, from age 18-50, 
appears to confer a greater risk of chronic diseases, such as cancer, than later 
life weight gain (7, 8). Also, those who are obese have been shown to have 
insulin resistance and chronic inflammation (9, 10); two of the five components of 
MetS.  
This research focused on obesity, MetS and inflammatory markers and 
their association with risk and mortality of breast and colorectal cancer. These 
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three inter-related studies as shown in the conceptual framework (fig. 1) were 
designed to meet the three publishable papers requirement.  
3 
SIGNIFICANCE 
Obesity is a growing global problem and accounts for 20% of cancer 
cases and deaths in the United States (11, 12).  In the US, 41% of the adult 
population is estimated to be obese (4, 13). The prevalence of obesity differs 
across demographic characteristics. When compared to men (33%), women 
(36%) are more likely to be obese (4, 13). According to the Center for Disease 
Control and prevention (CDC), non-Hispanic blacks have the highest age-
adjusted rates of obesity (47.8%) when compared to non-Hispanic whites 
(32.6%) (4, 14). Obesity rates also differ by age, middle aged (40-59) persons 
have a higher prevalence of obesity (39.5%) compared to young adults aged age 
20-39 (30.3%) (4, 14).  
Obesity is associated with the incidence and mortality of both colorectal 
cancer and post-menopausal breast cancer (6). Colorectal cancer (CRC) is the 
third most common cancer and the second most frequent cause of cancer-
related death among men and women in Western countries (15, 16).  Breast 
cancer is the most common cancer and the second leading cause of cancer 
mortality among women in the developed world (15, 16). Both breast and 
colorectal cancer can be prevented through maintaining a healthy weight (15, 
16).   
Excessive weight can be measured in the form of a person’s Body Mass 
Index (BMI: kg/m²) value, which is a common and universal anthropometric 
measure used to define obesity (17). Other anthropometric measures are those 
associated with visceral adiposity such as waist circumference and the waist-to-
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hip ratio (17). In understanding risk associated with unhealthy BMI, several 
aspects of excessive weight should be explored.  Longitudinal change in 
adiposity, cross-sectional measures of BMI and WC, MetS and CRP may add 
insights into the biological relationship of obesity with both breast and colorectal 
cancer.   
Several studies have assessed the association of weight gain and the risk 
of colorectal cancer (18-21). However, there are limited studies that have 
assessed the association of weight gain and risk of colon polyps (22, 23). Weight 
gain in earlier adult life from age 18-50, because it results in visceral fat 
accumulation (24), appears to confer a greater risk of chronic diseases than later 
life weight gain (7, 8, 25).  In addition, waist circumference (WC), as a reliable 
surrogate of visceral adiposity, is suggested to be a better predictor of colorectal 
cancer, because it is more closely related to obesity-associated cardio metabolic 
disorders (25). Unlike most other cancers, removal of the adenoma, which is the 
precursor lesion for colorectal cancer, renders an opportunity for prevention of 
cancers at that site (26). Therefore, understanding if BMI or WC changes are 
associated with an increased risk of advanced colorectal neoplasia (AN) may 
provide an opportunity to underscore the need to maintain a healthy weight to 
prevent development of advanced colorectal neoplasia and ultimately colorectal 
cancer.  
There is growing evidence on the impact of obesity biological markers, 
specifically MetS and CRP on the risk of cancer. It is estimated that 1 in 4 adults 
in the US have MetS (27, 28). MetS is a clustering of three or more of the 
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following: large waist circumference; elevated triglycerides, blood pressure, and 
fasting blood glucose; and low HDL cholesterol (29-31). These components have 
been shown to increase the risk of several cancers (32, 33), including breast 
cancer (1, 31, 34-37). The link between obesity and breast cancer is believed to 
be related to chronic inflammation (9, 10) while insulin resistance is the best 
established pathway linking obesity and colorectal cancer (38). Inflammatory 
responses are characterized by the increase of cytokines and markers of active 
inflammation (such as CRP and fibrinogen) (9, 10). High-sensitivity CRP has 
been investigated extensively as a robust marker of systemic inflammation for 
predicting the risk of cardiovascular disease (CVD) and diabetes (39, 40), but not 
in cancer. These three chronic diseases have obesity as a common risk factor. 
Obesity rates remain high among breast cancer survivors putting them at risk of 
recurrence of cancer and mortality (41, 42).  
It is under these premises, change in BMI and WC and obesity markers as 
risk factors to specific cancers, that this research was built. The first manuscript 
assessed change in adiposity measures (BMI and waist circumference) and their 
associated risk for advanced colorectal neoplasia. The second manuscript 
assessed obesity markers (MetS and CRP) among breast cancer survivors and 
compared them to healthy women. The last manuscript assessed the association 
of obesity markers with risk of breast and colorectal cancer mortality. The three 
studies are inter-related as shown in the following conceptual framework (fig. 1). 
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CHAPTER 1: BMI CHANGE AND RISK OF ADVANCED COLORECTAL 
NEOPLASIA 
Abstract  
Objective: There is strong evidence that obesity is associated with risk for 
colorectal cancer (CRC); however, little is known about how change in body 
mass index (BMI) and waist circumference (WC) measures from early adult life 
(age 21) influence the risk of advanced colorectal neoplasia (AN). The study 
objectives were to examine the association between BMI change and WC 
change and risk of AN, as well as to determine whether changes in BMI and WC 
better predict risk of AN when compared to static measures.  
 
Methods: A cross-sectional study of 4500 adults aged 50-80 years was 
conducted among participants undergoing first-time screening colonoscopies. 
Participants were excluded if they had previous CRC or adenomatous polyps, 
inflammatory bowel disease, or polyposis syndrome. Participants reported 
current weight, height and waist circumference and their historical measures at 
age 21. Models adjusted for known risk factors for colorectal neoplasia. 
 
Results: Participants who were obese in early adulthood and remained obese 
later in life, had an increased risk of AN (OR=1.87; 95% CI: 1.08-3.23) compared 
to those who maintained a normal BMI. Those with a stable high-risk WC 
(females ≥35 inches and males ≥40 inches) at age 21 and time of screening had 
increased risk of AN (OR=2.15; 95% CI: 1.35-3.45) compared to those with a 
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stable-low risk WC. For static measures, obesity at age 21 but not obesity at time 
of screening increased the risk of AN (OR=1.91, 95% CI: 1.22-3.00). Having a 
high-risk WC at age 21 and at screening compared to those with a low-risk WC 
was associated with increased risk of AN. Both static and dynamic measures 
have similar model statistics and were significantly associated with risk of AN. 
WC measures (static and dynamic) were generally better predictors of AN than 
BMI. The omnibus BMI variable at age 21, and the stable-obese indicator 
variable for BMI change, were significantly associated with AN when BMI was 
entered alone. However, when both BMI and WC were entered together in the 
models, only WC (not BMI) was significantly associated with AN (for both the 
“current” model and the “change” model) indicating that WC provided unique 
prediction of AN separate from the characteristics that WC and BMI share in 
common. 
 
Conclusions: Adiposity in early adulthood and maintaining an unhealthy BMI 
and WC from early adult life may increase an individual’s risk for advanced 
neoplasia. WC provided unique prediction of AN. 
 
Impact: These findings support growing evidence that early adult life adiposity 
and change in adiposity increases the risk of advanced colorectal neoplasia.  
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Introduction 
Colorectal cancer is a global public health problem (16), the third most 
common cancer and the third leading cause of cancer death in both men and 
women in the U.S. (43, 44). The American Cancer Society estimated 136,830 
new cases would be diagnosed and 50,310 colorectal cancer (CRC) deaths 
would occur in 2014 (44). In addition to regular screening to remove polyps, 
several preventable lifestyle factors, such as weight management, healthy diet 
and exercise, have been linked to reduced risk of colorectal cancer. Obesity is 
one of the established risk factors for CRC in both men and women (12, 45, 46), 
with a stronger link reported in men (41, 47, 48). Epidemiological data suggests 
that 30% to 70% increased risk of CRC can be attributed to obesity (49).  
Several studies have assessed the association of weight gain and the risk 
of CRC (18-21). However, only a few studies have assessed the association of 
weight gain and risk of precancerous colorectal polyps (22, 23). Although weight 
gain in adulthood results in visceral fat accumulation (7, 8, 24), which has been 
linked to risk of colorectal cancer and other chronic diseases (25), increase in 
weight over time may be a better indicator of risk for advanced colorectal 
neoplasia (the composite of colorectal cancer and advanced precancerous 
polyps) as compared to cross-sectional (static) waist circumference and body 
mass index (BMI) values (50) at specific points in time. There are even fewer 
studies assessing the impact of change in waist circumference on risk for 
advanced neoplasia (51). It is unclear whether the timing of weight gain or the 
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duration of being overweight or obese are relevant determinants of risk for 
advanced neoplasia (AN).  
We hypothesized that an increase in BMI and waist circumference from 
early (age 21) to later adulthood (time of screening) may be associated with an 
increased risk for advanced colorectal neoplasia. To test this hypothesis, we 
analyzed data from a cross-sectional study of participants aged 50-80 year who 
were having their first screening colonoscopy. The primary aim of the analysis 
was to determine the association of changes in BMI and waist circumference and 
the risk of having advanced colorectal neoplasia. Additionally, we sought to 
determine if changes in BMI or WC better predicted risk of advanced colorectal 
neoplasia compared to static measures. 
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Methods 
This study was conducted at Indiana University Medical Center in 
Indianapolis and was approved by the institutional review boards at Indiana 
University and the Richard L. Roudebush Veterans Affairs Medical Center, 
Indianapolis, Indiana. 
Study population. 
The study methods have been discussed in detail elsewhere (52). The 
study was initiated in December 2004 to assess the factors associated with the 
risk for advanced colorectal neoplasia (AN). Study participants were eligible for 
the study if they were aged 50 to 80 years and were undergoing first-time 
colonoscopy screening. Participants were initially recruited from two large 
corporations that provided screening colonoscopy for their employees, retirees, 
and their dependents. Due to slow uptake of screening colonoscopy through 
these company-based programs, additional recruitment was required from 
Indianapolis Gastroenterology and Hepatology, a large single-specialty practice 
in Indianapolis as well as from several of the affiliate hospitals of Indiana 
University Medical Center, including, Wishard Memorial Hospital, Roudebush 
Veterans Affairs Medical Center, and from Margaret Mary Community Hospital in 
Batesville, IN, which is an outreach site. Participants were excluded if they had 
previous colorectal cancer or adenomatous polyps, inflammatory bowel disease, 
or familial or non-familial polyposis syndrome.  
Eligible subjects who were already scheduled for screening colonoscopy 
received a letter of introduction describing the study along with a 12-page, 50-
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item self-administered questionnaire and a 72-inch tape measure. Participants 
received a follow-up call to clarify eligibility and answer questions about the 
study. The study questionnaire gathered data on a variety of factors: 
demographic variables, family history of colorectal cancer, personal medical 
history (including previous lower endoscopic procedure findings and non-
endoscopic screening test results), lifestyle habits (diet, exercise, cigarette 
smoking, alcohol use), medication use (particularly aspirin, non-steroidal anti-
inflammatory drugs, and post-menopausal hormone replacement therapy), and 
anthropometric measures. 
Weight and weight history 
Participants were asked about their weight, height, and waist 
circumference history. The weight history question was 1) “When you were age 
21, what was your approximate weight and approximate waist circumference?” 
The participants were also asked to estimate their current weight (without shoes) 
and their waist size. In addition, a tape measure and instructions were provided 
in the package for the participants to accurately record their waist circumference 
by measuring the smallest part, above the navel, body naturally erect, and 
abdomen neither drawn in nor protruded. On the day of the colonoscopy, nursing 
personnel at each site recorded physical measures (height, weight, waist and hip 
circumference). 
BMI was calculated as a ratio of weight and height (kg/m²) and grouped 
into three categories: normal (<25.00), overweight (≥ 25.00 to 29.99), and obese 
(≥ 30.00) using the World Health Organization’s criteria (53). In calculating BMI 
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change comparisons were made to assess changes in obesity over time: BMI at 
age 21 was the baseline BMI and was compared with that at Time 2 (current-time 
of screening). BMI changes were defined in 9 specific categories within three 
broad areas (54): A. Maintained BMI: 1) Stable-Normal: those whose BMI 
remained normal at both time points; 2) Stable-Overweight:  those whose BMI 
was overweight at both time points; and 3) Stable-Obese: those whose BMI was 
obese at both time points. B. Increased BMI: 4) Normal to Overweight: those 
whose BMI increased from normal to overweight, 5) Normal to Obese: those 
whose BMI increased from normal to obese; and 6) Overweight to Obese: those 
whose BMI increased from overweight to obese. C. Reduced BMI from 7) 
Overweight to Normal; 8) Obese to Overweight and 9) Obese to Normal.  
Self-reported waist circumference (WC) at age 21 and reported current 
WC were categorized into two risk groups using recommended international 
gender specific cutoffs: low risk (females <35 inches and males <40 inches) and 
high risk (≥35 inches for females and ≥40 inches for males) (29). WC change 
was categorized as follows: 1) Stable low-risk: those who had a low risk WC at 
both time points; 2) High-low risk:  those who had a high risk WC at age 21 but 
reduced to a low risk; 3) Low-high risk: those who had a low risk WC at age 21 
and increased to high risk and 4) Stable-high risk: those who had a high risk WC 
at both time points.  
Outcome Ascertainment 
Colonoscopy and pathology reports were reviewed and coded by trained 
personnel who were blinded to survey information. Results of the colonoscopies 
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were coded based on the most advanced histological findings. Advanced 
precancerous polyps were defined as an adenoma >1 cm or one with villous 
histology or high-grade dysplasia.  
Statistical Analysis 
Descriptive statistics comparing the characteristics of those with and 
without advanced colorectal neoplasia (advanced neoplasia) were performed. 
Pearson chi-square tests and two-sided t-tests were performed to compare the 
distributions and means of covariates and exposures of interest (BMI and waist 
circumference) by advanced neoplasia status. Multiple logistic regression 
analysis was used to estimate the risk of advanced neoplasia based on changes 
in BMI and changes in waist circumference. Three separate models were 
assessed: 1) BMI change alone as the risk factor; 2) waist circumference change 
alone as the risk factor; and 3) both change in BMI and change in waist 
circumference as the risk factors. Very few participants reduced their BMI (n=11) 
or reduced their WC-high-low risk WC (n=26), therefore, these individual cases 
were excluded from the analytical dataset. The statistical power has a reduced 
chance of detecting a true effect. These exclusions led to reduced BMI change 
and WC change categories. Two broad BMI change categories and 6 specific 
categories were used in the models with maintenance of normal weight as the 
reference category. For WC change three categories were used with 
maintenance of a low-risk WC as the reference category. Several known risk 
factors for CRC were controlled in the logistic model: age, race, gender, 
education, smoking, NSAID use, physical activity, alcohol intake, family history, 
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red meat intake, vegetable intake, and estrogen use in women (55). These 
factors were assessed as confounding variables by comparing the crude and 
adjusted odds ratios (OR) of the BMI/waist circumference risk factors in the 
presence of potential confounders.  
To assess whether the dynamic measures (change from age 21 to time of 
screening) of BMI and waist circumference were better at predicting risk of 
advanced neoplasia, compared to the static measures, we focused on the model 
statistics when the individual variables were included in the analyses together 
with the confounding factors. The variables of interest (static BMI, static WC, 
dynamic BMI, and dynamic WC) were entered into separate models. In addition, 
static BMI and WC variables were entered together, and both BMI change and 
WC change were simultaneously considered, to determine whether BMI or WC 
could add significant unique association with AN after adjusting for each other. 
Both dynamic and static measures of BMI and WC were correlated. The 
Spearman correlations for BMI and WC were: at age 21 rho=0.31, p-value 
<.0001, at time of screening rho=0.56, p-value <.0001 and WC change and BMI 
change rho=0.39, p-value <.0001. Since the variables were correlated, we 
assessed collinearity diagnostics. Other than a minor collinearity involving the 
intercept, the collinearity diagnostics did not indicate that the correlations of the 
two measures at the different time points were affecting the conclusions drawn 
from the analysis. Static and dynamic measures were not entered in the model 
together because they were highly correlated and collinearity problems were 
observed. The static and dynamic BMI variables were not entered together in the 
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same model, nor were the static and dynamic WCs variables, because this would 
have resulted in statistical redundancy. The dynamic variables are created from 
the static measures and therefore, share a lot of the variation in predicting AN. 
The model statistics of interest were Akaike Information Criterion (AIC), c-
statistic, the Type 3 (i.e., adjusted for other variables in the model) omnibus 
likelihood ratio test for the variable of interest, and the Hosmer and Lemeshow 
goodness-of-fit test. Models with lower AIC, higher c-statistic, and lower p-value 
were considered better models statistically. All statistical analyses were 
performed using SAS for WINDOWS software, version 9.4. P-values less than 
.05 were considered statistically significant. 
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Results 
The mean age of the participants was 57.3 (± 6.8) years; 52% were 
women. Most of the study participants were non-Hispanic whites and had lower 
levels of education. Descriptive characteristics of the participants are 
summarized in Table 1.1. Those with advanced neoplasia were more likely to be 
men, and to have higher rates of CRC in their families, cigarette smoking, alcohol 
use, Aspirin/NSAID intake and red meat intake, and lower rates of vegetable 
intake and reported physical activity. Women with AN reported high rates of 
estrogen use. 
Association of Static BMI and Waist Circumference and AN Risk 
Table 1.2 shows regression results comparing static measures of BMI and 
waist circumference at different time points on the risk of AN. At age 21, being 
obese and having a high risk WC was significantly associated with increased risk 
of AN. At the time of screening colonoscopy, WC but not BMI was associated 
with increased risk of AN.  More importantly, only WC at the time of screening 
remained significant when both BMI and WC were in the model. Neither WC nor 
BMI at age 21 were significant when both were in the model. 
Association of BMI Change and Waist Circumference Change and Risk of AN 
Table 1.3 shows the results of multiple logistic regressions analyses 
assessing the relationship between change in BMI and change in WC on the risk 
of AN. Maintaining obesity status between age 21 and current age (stable-obese 
compared to stable-normal) was positively associated with AN (OR=1.87). 
Increasing BMI was associated with numerically increased but statistically non-
18 
significant risk of AN. Stable-high risk WC was associated with increased risk of 
AN, irrespective of whether changes in WC and BMI were modeled separately or 
together. Increase in WC (low-high risk) was associated with numerically 
increased but statistically non-significant risk of AN. When both WC change and 
BMI change were adjusted for each other, none of the BMI change categories 
were significant. However, those with a stable-high risk WC (OR=2.49) and those 
who increased their WC from low-high risk (OR=1.43), from age 21 to time of 
screening, had increased risk for AN, irrespective of whether BMI change was 
considered (Table 1.3). 
To assess whether the dynamic measures (BMI change and WC change) 
were better at discriminating between participants with versus without AN, 
compared to the static measures (current and age 21) of BMI and waist 
circumference, we focused on the model fit statistics as shown in Table 1.4. 
Overall, the models, including covariates, were comparable in terms of predictive 
power and goodness-of-fit. As indicated by the c-statistic, all models had a high 
(76%) and comparable predictive power to discriminate those with AN from those 
without. Furthermore, as shown by the Hosmer and Lemeshow goodness of fit, 
the data fit well in all the models. For all models, the likelihood ratio test of the 
significance of the overall model had chi-square values that were significant. As 
expected, the base model (with covariates only) had the largest AIC indicating 
that the model was improved when adding either BMI or WC. Therefore, we 
focused on the omnibus test for the variable of interest. 
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Overall, models with dynamic measures and those with static measures 
did not differ substantially in discriminating those with versus those without AN.  
However, WC was generally a better predictor of AN than BMI when comparing 
models with either change or static measures at age 21 and at the time of 
screening. Even when BMI and WC were assessed in the model together, WC 
remained significant in predicting risk of AN, except at age 21. It was noted that 
results from this study was that in general, models with BMI and WC measured 
at age 21 had better model statistics compared to models with BMI and WC 
measured at the time of screening. 
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Discussion 
In this study, we observed a positive association of waist circumference 
and BMI in early adult life (age 21) but only waist circumference at the time of 
screening, with risk of advanced colorectal neoplasia. To our knowledge, this is 
one of the few studies to examine the association of both BMI and waist 
circumference change with the risk of advanced colorectal neoplasia. Maintaining 
an obese status or a high risk waist circumference over time was associated with 
increased risk of AN. The data fit well in models with both static and dynamic 
measures, with no substantial differences in overall model statistics (such as AIC 
and c-statistic) when dynamic or static measures of BMI and WC were used to 
predict risk of AN. However, WC was generally a better predictor of AN when 
compared to models with BMI. 
There are limited studies conducted on the association between advanced 
neoplasia and weight change. A large case control study by Bird et al, showed 
that large weight increases during adulthood were associated with adenomatous 
polyps (22). That study assessed weight change as the difference between 
current weight, weight gained 10 years before sigmoidoscopy and weight at age 
18.  Compared to those who reported a weight loss, those with net weight gains 
of 1.5-4.5kg had increased odds of adenoma (OR=2.5; 95% CI: 1.2-5.6) (22). In 
another study, weight gain over the past 10 years prior to screening was 
significantly associated with increased risk of colon adenomas (OR=2.2; 95% CI: 
1.0-4.8), ≥ 6kg vs -2 kg (23). We conducted a sensitivity analysis using similar 
methods and actual weight difference, but did not find any significant weight 
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groups (OR= 1.0; 95% CI: 0.70-1.36 Quartile 4 vs Quartile 1) associated with risk 
for AN. The association of weight change and risk of colorectal cancer has been 
studied but the results are conflicting. In some studies, weight increase has been 
associated with increased risk for colorectal cancer (18, 34, 56) while others did 
not find a significant relationship (19). 
Waist circumference is considered a reliable surrogate of visceral obesity 
because it is more closely related to obesity-associated cardio metabolic 
disorders (25, 57). To our knowledge, this may be the first study to examine the 
association of waist circumference change and risk of AN. The findings of our 
study indicate that participants who at age 21 and at screening had waist 
circumference equal to or larger than the recommended maximum value (women 
35 inches and men 40 inches) had increased risk of advanced neoplasia and the 
risk was higher when BMI change was adjusted in the analyses. Also those who 
increased their WC from age 21 to time of screening had an increased risk of AN, 
but only when their change in BMI was adjusted in the model. The highest risk for 
AN was observed in the WC change measure compared to the static measures. 
When both BMI change and WC change were in the model together, WC change 
remained significant; this conveys that WC change provides a significant 
association with AN after removing or adjusting for the effects of BMI change. 
These results indicate that WC provided unique prediction of AN separate from 
the characteristics that WC and BMI share in common.  
The findings of this study that WC and BMI at age 21 are associated with 
risk of AN are unique and of potential public health importance. These results 
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add to new evidence that early adult life body adiposity may affect the risk of 
colorectal cancer many decades later (58, 59). Having a large WC at age 21 was 
associated with an increased risk of AN (OR=1.9); this may be the first study to 
show this association. Our findings indicate that being obese (BMI ≥30) at age 
21, but not at screening was associated with increased risk of AN. Our findings 
differ from those in a study by Bird et al., which sought to examine the 
association between colorectal adenomas with BMI over time. Bird et al., 
reported that BMI at exam (OR=1.4; 95% CI: 1.0-2.0, Quartile 2 vs Quartile 1) 
was associated with increased risk for adenomas (22), but found no association 
between BMI at age 18 and risk for adenomas (22). To define early adult life we 
used age 21 while Bird et al. used age 18. It is possible that this 3 year age 
difference accounts for the discrepant findings, although the age difference is 
small. Perhaps the time between ages 18 and 21 may be important as it is 
related to the difference between early and late full adult development. Another 
reason for the discrepant findings may be in how BMI was categorized. We 
categorized BMI using WHO criteria but Bird and others have used continuous 
BMI categorized in quartiles. Therefore, while current measures of WC and BMI 
are important, we may consider  an individual’s measures at early adult life to 
better predict risk, which further underscores the importance of weight 
management early in life to prevent AN.  
Another novel aspect of this study was that we examined whether 
changes in BMI and WC better predict risk of AN when compared to static 
measures. The findings of our study indicate that dynamic measures of BMI and 
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WC were not substantially different in predicting risk of AN compared to the static 
measures. However, the WC measures overall were better at predicting risk of 
AN compared to the BMI measures. This may be supported by the fact that waist 
circumference is strongly related to visceral obesity than BMI. One remarkable 
finding was that BMI and WC measured at age 21 were better at predicting AN 
compared to static measures at screening. There is growing evidence that early 
adult life obesity measures are associated with future risk of some cancers (58, 
59) making the results of our study important for managing population health. 
Knowledge of the potential of future risk in early adult life underscores the need 
to maintain healthy behaviors early in life. Additionally, dynamic measures may 
be useful in identifying and stratifying those who are most at risk for AN.  
The results of the current study support the link between obesity and 
increased risk of colorectal cancer (38, 46, 60). The findings of the current study 
are strengthened by the concurrent assessment of both waist circumference and 
BMI in relation to risk of advanced colorectal neoplasia. In adulthood, waist 
circumference has been shown to be a better predictor of obesity-related health 
risk than BMI (61). Indeed a combination of both BMI and waist circumference 
has been shown to better estimate the health risk than either factor alone (62). 
This is because health risk increases from the normal weight through obese BMI 
categories, but within each BMI category, those with higher waist circumference 
values have a greater health risk than those with normal waist circumference 
values (63). Although we did not create a single variable that combined both 
waist circumference and BMI, we adjusted for the effect of the other in the 
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regression models. Additional strengths of the study include the large sample 
size and weight history assessment. The findings of this study may be 
generalizable to the non-Hispanic white population who were a majority in the 
study. Although, most of the participants were non-Hispanic white, the obesity 
rates in our study are comparable to  the national age-adjusted obesity rates 
(35.9% vs 34.9%) (64). 
Study limitations are those inherent in an observational study. There was 
the possibility of intentional and unintentional errors in self-reported height and 
weight which were used to calculate BMI. However, self-reported and measured 
weights have previously been reported to be highly correlated (65, 66). The 
associations were modeled based on self-reported historical weight and height, 
which may lead to a recall misclassification of waist circumference and BMI.  
However, it is likely that the same amount of misclassification (non-differential) 
occurred in those with and without AN, so the misclassification error may not 
have affected the study findings. In this study we could not assess the impact of 
BMI decrease on risk of advanced neoplasia because so few subjects reduced 
their weight. Nonetheless, we adjusted several of the known colorectal cancer 
risk factors in an attempt to isolate the specific impact of adiposity measures on 
advanced colorectal neoplasia. Finally, our assessment was based on neoplasia 
diagnosis rather than occurrence of AN, which may have developed a 
considerable amount of time before the diagnosis, and this lag time may have led 
to errors in estimating the period at risk. Due to these limitations, causal 
relationships should not be drawn from this study. 
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In conclusion, our results support previous findings that early adulthood 
BMI and maintaining an unhealthy BMI and waist circumference are independent 
risk factors for AN. Both static and dynamic measures have similar overall model 
statistics, and both were significant predictors of the risk of AN. The results 
emphasize the importance of maintaining a healthy BMI throughout adult life for 
preventing AN. Weight gain expressed in terms of movement between BMI 
categories may be more practical and useful in clinical practice than current 
measures alone but this remains to be determined from future studies. Health 
care providers may use the findings as a prevention strategy for colorectal 
cancer when counseling patients, in line with the American Society of Clinical 
Oncology’s prioritization of educating providers and patients on the role of energy 
balance as a strategy to reduce the impact of obesity on cancer (67). Prospective 
studies should be conducted to validate our findings and to explore the 
associations of reducing, increasing and maintaining BMI (as well as changes in 
waist circumference) and risk of advanced colorectal neoplasia.   
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Table 1.1 Characteristics of Study Subjects by Advanced Neoplasia 
Status 
 Advanced 
Neoplasia 
(n=410) 
No-Advanced 
Neoplasia 
(n=4,090) 
  
 Mean (SD) t value p value 
Age (year) 61.4 (9.0) 56.9 (6.3) 568.7 <.0001 
Pack years 20.8 (26.1) 8.7 (16.6) 36.5 <.0001 
Vegetable intake-wkl 15.1 (8.2) 15.9 (7.5) 140.0 0.05 
Red meat intake-wkly 5.1 (3.0) 4.1 (2.5) 111.3 <.0001 
 n (%) X² [DF]  
Gender     
Male 250 (61.0) 1,928 (47.1) 28.6 [1] <.0001 
Female 160 (39.0) 2,162 (52.9)   
Education     
High School  152 (37.1) 1060 (26.0) 47.8 [3] <.0001 
Trade/Vocational 62 (15.1) 401 (9.8)   
College Educatio 141 (34.4) 1682 (41.2)   
Postgraduate 55 (13.4) 940 (23.0)   
Race  
Non-Hispanic 
White 358 (87.3) 3884 (95.0) 76.8 [2] <.0001 
Non-Hispanic 
Black 
44 (10.7) 106 (2.6)   
Other 8 (1.9) 100 (2.4)   
Alcohol Use  
No problem 
drinking 357 (87.07) 3704 (90.67) 5.54 [1] 0.02 
Problem 
drinking 53 (12.93) 381 (9.33)  
 
Aspirin-NSAID intake 
Low 258 (62.9) 2649 (64.8) 6.6 [2] 0.04 
Medium 46 (11.2) 581 (14.2)   
High 106 (25.9) 860 (21.0)   
Estrogen (Females) 
No 37 (23.1) 918 (42.3) 23.3 [1] <.0001 
Yes 123 (76.9) 1238 (57.4)   
Exercise     
0-<2 hrs./week 239 (58.3) 1743 (42.6) 38.7 [2] <.0001 
2 to 
<4hrs./week 
153 (37.3) 2054 (50.2)   
>4 hrs./week 9 (2.2) 102 (2.5)   
Family History of Colorectal Cancer 
Yes 55 (13.4) 372 (9.1) 8.1 [1] 0.004 
No 355 (86.6) 3718 (90.0)   
  
 
  Table 1.2 Association of BMI and Waist Circumference at different Time points and risk of Advanced 
Neoplasia 
 Measures at Age 21 Measures at Time of Screening 
 
Models a 
WC and BMI in 
separate models 
Model b 
WC and BMI in 
model together 
Models a 
WC and BMI in 
separate models 
Model b 
WC and BMI in 
model together 
BMI Categories  
Underweight/Normal (<25 Kg/m²) Reference Reference Reference Reference 
Overweight (25-29.99  Kg/m²) 1.27 (0.96-1.67) 1.22 (0.92-1.62) 1.02 (0.76-1.37) 0.92 (0.68-1.26) 
Obese (≥30  Kg.m²) 1.91 (1.22-3.00) 1.62 (0.97-2.69) 1.07 (0.79-1.45) 0.81 (0.56-1.19) 
Waist Circumference Categories 
Low Risk  Reference Reference Reference Reference 
High Risk  1.85 (1.19-2.86) 1.45 (0.88-2.39) 1.29 (1.02-1.63) 1.43 (1.06-1.93) 
The table shows results of analyses conducted for each time point to assess the association of individual 
anthropometric measurements (where applicable, both waist circumference and BMI are in the model) and risk 
of advanced colorectal neoplasia. All models were adjusted for age (continuous), race (non-Hispanic white, 
non-Hispanic black, Other), gender (male vs female), and education (high school, trade/vocational, college 
education and postgraduate), family history of colorectal cancer (yes/no), smoking (pack years), exercise, 
alcohol use (yes/no), red meat intake (daily), vegetable intake (daily), use of aspirin /other NSAIDs and 
estrogen use (yes/no).  
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Table 1.3 Association of BMI Change, Waist Circumference Change and risk of Advanced Neoplasia 
 Change from Age 21 to Current 
 
Distribution of those with 
AN 
n (%) 
Models a 
WC change and BMI 
change in separate 
models 
Model b 
WC change and BMI 
change in model 
together 
Waist Circumference change    
Stable-Low risk 199 (49.63) Reference Reference 
Low-High risk 175 (43.64) 1.23 (0.97-1.57) 1.43 (1.05-1.96) 
Stable-High risk 27 (6.73) 2.15 (1.35-3.45) 2.49 (1.38-4.51) 
BMI Change    
Maintained BMI    
Stable-Normal BMI  81 (20.98) Reference Reference 
Stable-Overweight  37 (9.59) 1.54 (0.97-2.45) 1.37 (0.86-2.20) 
Stable-Obese  23 (5.96) 1.87 (1.08-3.23) 1.01 (0.52-1.99) 
Increased BMI    
Normal to Obese  80 (20.73) 1.14 (0.80-1.62) 0.87 (0.57-1.33) 
Normal to Overweight  113 (29.27) 1.00 (0.72-1.38) 0.90 (0.64-1.26) 
Overweight to Obese  52 (13.47) 1.04 (0.69-1.57) 0.74 (0.46-1.19) 
The table shows results of several analyses conducted to assess the association of individual and 
combined measurements and risk of advanced colorectal neoplasia.  All models were adjusted for age 
(continuous), race (non-Hispanic white, non-Hispanic black, Other), gender (male vs female), and education 
(high school, trade/vocational, college education and postgraduate), family history of colorectal cancer 
(yes/no), smoking (pack years), exercise, alcohol use (yes/no), red meat intake (daily), vegetable intake 
(daily), use of aspirin /other NSAIDs and estrogen use (yes/no). 
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Table 1.4 Statics to compare models with Static and dynamic measures of Body Mass Index (BMI) 
and Waist circumference 
 AIC c-stat 
Likelihood Ratio Test 
for overall model 
Type 3 Omnibus Likelihood 
Ratio Test  of Variable of 
Interest 
Hosmer and Lemeshow 
Goodness-of-Fit Test 
   
 
D
F 
p-value   DF 
p-
value  
DF p-value 
M0:   Base model-covariates 
only 
2306 0.754 370.78 21 <.0001  1.9806 8 0.98 
Static Measures            
M1:   M0 + BMI Current 2289 0.758 362.57 23 <.0001 0.23 2 0.89 1.81 8 0.90 
M2:   M0 + BMI at age 21 2274 0.759 371.70 23 <.0001 8.93 2 0.012 8.05 8 0.43 
M3:   M0 + Waist Current 2281 0.760 367.66 22 <.0001 4.59 1 0.03 4.00 8 0.86 
M4:   M0+ Waist at age 21 2279 0.759 370.78 22 <.0001 6.81 1 0.009 10.41 8 0.24 
M5:   M0 + BMI Current + WC 
Current 
2279 0.759 363.09 24 <.0001 
BMI: 1.20 2 0.55 
3.53 8 0.90 
WC: 5.56 1 0.02 
M6:   M0 + BMI age 21 + Waist 
age 21 
2269 0.760 369.36 24 <.0001 
BMI: 4.24 2 0.12 
6.58 8 0.58 
WC: 2.04 1 0.15 
Dynamic Measures            
M7:   M0 + BMI Change 2215 0.757 344.63 26 <.0001 8.49 5 0.13 8.02 8 0.43 
M8:   M0 + Waist Change 2259 0.762 368.53 23 <.0001 10.18 2 0.006 3.07 8 0.92 
M9:   M0 + BMI Change + WC 
Change 
2189 0.761 346.98 28 <.0001 
BMI: 5.49 5 0.36 
6.29 8 0.62 
WC: 9.87 2 0.007 
M0 = age (years), gender, race (non-Hispanic white, non-Hispanic black, Mexican American, and other race), 
education (no education, less than high school, high school, college education, and graduate education), 
family history of colorectal cancer, smoking (pack years), exercise (low, moderate, high), alcohol use (yes or 
no), red meat intake, vegetable intake, use of aspirin /other NSAIDs and estrogen use (yes/no).  
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CHAPTER 2: METABOLIC SYNDROME AMONG BREAST CANCER 
SURVIVORS 
Abstract 
Purpose: Several studies suggest that breast cancer risk is associated with 
metabolic syndrome (MetS) and C-reactive protein (CRP), but no nationally 
representative study has investigated CRP and MetS among breast cancer 
survivors. This study investigated the distributions and proportions of CRP, MetS, 
and its components (high fasting glucose and triglycerides, low HDL-cholesterol, 
high blood pressure, and abdominal obesity) among breast cancer survivors and 
their associations with breast cancer risk in a large nationally representative 
sample of US adults.   
 
Methods: Women aged 50 and above enrolled in the National Health and 
Nutrition Examination Survey 2005-2010-NHANES were included in the study. 
Pregnant women, those with other cancer diagnosis, as well as those with 
diabetes and cardiovascular diseases were excluded, resulting in a sample 
2,172, of which 172 were breast cancer survivors. MetS was defined as the 
presence of three or more MetS components. Models were adjusted for known 
risk factors for breast cancer. 
Results: The prevalence of MetS among breast cancer survivors was 42.6% and 
this prevalence did not differ significantly from the 44.2% prevalence among 
women without breast cancer. Neither MetS (OR=0.92, 95% CI: 0.53-1.60, MetS 
diagnosis vs. no MetS diagnosis) nor elevated CRP (OR=1.04, 95% CI: 0.45-
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2.42, CRP ≥1.0mg/dl vs <1.0mg/dl) were associated with increased risk of breast 
cancer. However, those with 3 abnormal MetS components had a non-significant 
association with breast cancer. The individual MetS components measured did 
not show a significant association with breast cancer. Only waist circumference 
(OR=1.29, 95% CI: 0.82-2.04) and HDL (OR=1.19, 95% CI: 0.74-1.91) had 
increased but non-significant association with breast cancer. Also, there was no 
joint association of MetS and CRP with risk of breast cancer.  
 
Conclusion: These null findings challenge the assumption that MetS and CRP 
which are directly linked to obesity are prevalent and associated with breast 
cancer risk. This supports the need to assess differences by survival years in a 
larger prospective study.   
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Introduction 
Breast cancer is the second most prevalent cancer among women in 
developed countries (16, 68). In the US it is estimated that 1 in 8 women will be 
diagnosed with breast cancer in their lifetime (68). The 5-year survival rate for 
localized breast cancer is 99% (69). However, breast cancer recurrence remains 
a major concern among survivors. Obesity has been repeatedly shown to 
increase the risk for breast cancer recurrence and mortality (42, 70-72). 
Obesity is a growing public health problem and the second most 
preventable cause of death (1). In the US one in three (37%) women is obese 
(2).  Obesity is the major determinant of MetS, which has been linked an 
increased risk of breast cancer (36). MetS is defined as a cluster of at least three 
of the following five factors: high-density lipoprotein (HDL) cholesterol (<50 mg/dl 
for women), triglycerides (≥150 mg/dl), systolic blood pressure (≥130 mm Hg), 
fasting blood glucose (≥100 mg/d) and waist circumference (≥88 cm for women) 
(29-31). It is estimated that 33% adult women in the US have MetS (27, 28). The 
link between obesity and breast cancer is believed to be related to chronic 
inflammation which induces aromatase expression and estrogen synthesis (9, 
10). Inflammatory responses are characterized by the increase of cytokines and 
markers of active inflammation (such as CRP and fibrinogen) (9, 10). High-
sensitivity CRP has been investigated extensively as a robust marker of systemic 
inflammation for predicting the risk of cardiovascular disease (CVD) and diabetes 
(39, 40). Elevated CRP has been previously proposed as a component of the 
MetS (73). A few studies have examined the relationship of MetS and CRP with 
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breast cancer risk, recurrence, and survival but the results have been 
inconsistent (74-76). 
A number of studies have examined the relationship between obesity and 
breast cancer; however, few nationally representative population studies have 
examined the relationship between MetS and CRP in breast cancer cases as 
compared to cancer-free women (75, 77, 78).  Furthermore, there is limited 
research on the joint association of CRP and MetS on the risk of breast cancer 
(77). Therefore, we first sought to examine the distribution and prevalence of 
obesity markers (CRP and MetS) among breast cancer survivors compared to 
those free of breast cancer from the NHANES data. Second, we examined 
whether CRP and MetS (and its individual components) were associated with 
breast cancer diagnosis. Lastly, we further explored if CRP and the MetS jointly 
modified risk of breast cancer. A better understanding of the presence of MetS 
and CRP among breast cancer survivors will help support the management of 
comorbid metabolic disorders. 
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Materials and Methods 
Study Design and Study population 
To answer the research questions, data for this study were obtained from 
the National Health and Nutrition Examination Survey (NHANES). The design, 
questionnaires, and examination methodology of NHANES are described in 
detail at the Center for Disease Control and Prevention (CDC) website (79). The 
data used in this study were from the 2005/06, 2007/08 and 2009/10 surveys 
(n=2,172 who had CRP or MetS components measured). In these three surveys, 
low-income individuals, individuals 60 years of age and older, African Americans 
and Mexican Americans were oversampled; therefore, sampling weights were 
added to allow the estimates to be generalizable to the US population. The 
NCHS Institutional Review Board approved the survey protocols, and informed 
consent was obtained from all subjects. The present study was not reviewed by 
the Institutional Review Board of Indiana University as the data analyzed are de-
identified and publicly accessible.  
Women who participated in the NHANES study were eligible if they were 
50 years or older to limit the study to post-menopausal breast cancers. Women 
were excluded if they were pregnant and had been diagnosed with cancers other 
than breast cancer. Breast cancer survivors were compared with women without 
breast cancer diagnosis. The controls who had been diagnosed with diabetes or 
cardiovascular diseases were excluded because these two diseases were 
strongly linked to MetS. A total of 2,172 women met the study inclusion and 
exclusion criteria, of these 172 women were breast cancer survivors.   
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Variables 
The outcome variable of interest was having or not having a breast cancer 
diagnosis. Participants who reported being diagnosed with breast cancer were 
defined as the ‘cases’ while those without a diagnosis of cancer were defined as 
‘controls.’  The exposure variables were MetS and CRP. The components of 
MetS (waist circumference, triglycerides, HDL-cholesterol, blood pressure and 
blood glucose) were measured during the physical examination. Waist 
circumference was determined at the iliac crest after a normal exhalation of 
breath. Serum concentrations of HDL-cholesterol and triglycerides were 
measured enzymatically with Hitachi 704 Analyzer. Fasting blood samples were 
drawn by a trained phlebotomist to assess blood glucose levels. Serum fasting 
glucose levels were determined using the glucose hexokinase method with 
Hitachi 737 Analyzer. Systolic blood pressure (mmHg) was measured using a 
mercury sphygmomanometer while subjects were in a seated position. Three 
measurements were taken and then averaged for each subject to minimize 
measurement error (80). High sensitivity CRP concentration was quantified using 
latex-enhanced nephelometry, and reported in mg/dl to the nearest hundredth 
(0.01) (80). 
 
Statistical Analysis 
Chi square and t-tests were performed to compare the crude distributions 
and means of exposure variables and covariates by breast cancer status. 
Multiple logistic regression analysis was used to measure the association 
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between obesity makers (MetS and CRP) and the prevalence of breast cancer 
while controlling for the covariates: age, race/ethnicity, education, marital status, 
age at menarche, age at menopause, smoking, hormone replacement and 
alcohol intake. A weight statement and variable were included in the Proc 
SurveyLogistic SAS analysis model. Two models of each variable of interest 
were conducted with different covariates: Model 1 was adjusted for age and race 
and Model 2 was controlled for all the listed covariates. 
To assess the joint effects of CRP and MetS on breast cancer risk we 
defined four categories using both CRP and MetS variable. The categories were: 
1) Low-risk defined as no MetS diagnosis and low CRP levels; 2) High risk I 
defined as participants with no MetS diagnosis but with an elevated CRP; 3) High 
risk II defined as participants with a MetS diagnosis but with low CRP level; 4) 
High Risk III defined as participants with a MetS diagnosis and with elevated 
CRP. This composite variable and the covariates were entered as an 
independent variables in a multiple logistic regression analysis. For all analyses 
SAS version 9.4 was used and P-values less than .05 were considered 
statistically significant. 
The NHANES database included measures of all components of MetS 
and CRP available for analysis. However, the CRP values were missing twenty 
percent of the participants, which was one of the exposure variables of interest. 
Those with missing CRP were assessed but no apparent pattern demographic or 
clinical patterns were identified. Therefore, CRP was imputed using multiple 
imputations (81, 82). Multiple imputations allow all participants to be included in 
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the analysis and therefore, preventing biased estimates of the association 
between MetS and CRP with the breast cancer diagnosis outcome. SAS 
software was used to generate imputed data. First, using PROC MI, 30 
imputation files were created. Multiple logistic regressions were then conducted 
by imputation files using the procedure PROC MI analyze. All covariates stated 
above were included in the PROC MI analyses. 
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Results 
Of the 2,172 eligible women who met the inclusion criteria, 172 were 
breast cancer survivors. The demographic and clinical characteristics of the 
study population are presented in Table 2.1. The majority of women enrolled 
were non-Hispanic white, married, non-smoking and with a college education. 
The prevalence of MetS among breast cancer survivors (42.6%) was not 
significantly different from that of the control group (44.2%). Although non-
significant, breast cancer survivors overall had better measures of the 
components of MetS compared to women without breast cancer. The survivors 
had enlarged WC, but lower fasting blood glucose, triglycerides and HDL levels, 
though the means did not significantly differ from the means in the controls. The 
breast cancer survivors had a significant and slightly higher mean CRP level 
compared to the controls. 
Table 2.2 shows the association of components of MetS and CRP among 
breast cancer survivors compared to the control. After adjustment for all 
covariates, WC was not significantly associated with (OR=1.29, 95% CI 0.82-
2.04) breast cancer survivors compared to women with no breast cancer. Neither 
was HDL (<50mg/dl vs. ≥50mg/dl) associated with breast cancer diagnosis. All 
the other components-triglycerides, blood pressure and blood glucose-when 
comparing those with high risk and low risk were also found not to be associated 
with risk of having a breast cancer diagnosis.  
Table 2.3 shows the association of MetS as a composite variable with 
breast cancer risk. In the adjusted multiple logistic regression model, breast 
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cancer risk was not associated with MetS when those with MetS were compared 
to those without MetS (OR=0.92, 95% CI: 0.53-1.60). The severity of MetS 
defined as having 3, 4 or 5 abnormal components was also not associated with a 
breast cancer diagnosis. CRP was not associated with breast cancer 
survivorship when women with CRP ≥ 1.0mg/dl were compared to those with 
CRP <1.0mg/dl (OR=1.04, 95% CI: 0.45-2.42). In a joint association model of 
CRP and MetS (Table 2.4) on breast cancer risk, no association was found for 
those with both elevated CRP and MetS with risk for breast cancer.  
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Discussion 
Findings from this study indicate that the prevalence of MetS and CRP 
values among breast cancer survivors do not differ significantly from the 
prevalence among healthy women based on a nationally representative sample 
in the US. Hence the presence of MetS diagnosis and elevated CRP were not 
associated with breast cancer risk. Furthermore, of the individual components of 
the MetS, none showed a significant association with breast cancer.  
The prevalence of MetS among breast cancer survivors in this study was 
high, but did not differ significantly from the prevalence in the healthy control 
group. Other studies have reported similarly high prevalence of MetS among 
breast cancer survivors (74-76). Our primary question was to assess the 
association of MetS with breast cancer risk. Although the prevalence of MetS has 
been shown to be high among breast cancer survivors, very few studies have 
compared survivors with healthy controls. The results of this study did not show a 
significant difference in MetS and its components, among breast cancer survivors 
compared to women without a diagnosis of breast cancer. However, other 
studies compared breast cancer survivors with a control group and found that 
MetS was higher in the breast cancer group (75, 83). Results of studies 
examining the association of MetS with incident and overall breast cancer risk 
have been inconsistent (84-88) .  
Waist circumference was associated with risk of breast cancer in some 
studies (83). However, consistent with our results, other studies have not found 
waist circumference to be associated with a diagnosis of breast cancer (83, 86, 
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87). While waist circumference is a reliable surrogate of visceral obesity because 
it is more closely related to obesity-associated cardio metabolic disorders (25, 
57), BMI is a more widely used obesity measure. Some studies used BMI in 
place of waist circumference when defining MetS and found increased BMI to be 
associated with risk of breast cancer (84). We conducted sensitivity analysis 
using participant’s current BMI but the association of being obese (BMI≥ 30) and 
breast cancer was not significant in the current study (OR=0.98, 95% CI: 0.63-
1.53).  
High fasting blood glucose levels have been associated with breast cancer 
risk in some studies (83, 86). However, other studies (84, 87, 89) did not find a 
significant association, as was the case in this current study. As an alternative to 
fasting blood sugar, one study used diabetes diagnosis as one of the 
components of the MetS and found a significant association (85). Blood pressure 
either reported as actual values or defined as having a hypertension diagnosis 
has been used as one of the components of MetS. Similar to both waist 
circumference and blood glucose levels the results of studies examining the 
relationship between high blood pressure with breast cancer have been 
inconsistent. High blood pressure was found to increase risk of breast cancer in 
some studies (83, 85, 89) and, like our current study, other studies did not find a 
significant association (84, 86, 87).  
Our study assessed separately the associations of high triglycerides levels 
and low HDL cholesterol levels with breast cancer risk. Wang et al. and Rosato 
et al. assessed the association of dyslipidemia (proxy of triglycerides and HDL 
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cholesterol) with breast cancer risk (84, 85). In the study by Wang et al., 
dyslipidemia was associated with 3.2 higher odds of postmenopausal breast 
cancer (84). However, hyperlipidemia was not associated with an increased risk 
of breast cancer (OR=1.08; 95% CI: 0.95-1.22) (85). Although our study and 
other studies (86, 89) did not find an association of triglycerides and HDL-
cholesterol with breast cancer risk, other studies reported significant associations 
(83, 87).  
Studies evaluating the association between CRP, a marker of systemic 
inflammation, and breast cancer risk are limited and the results were 
inconsistent. In our study of 172 breast cancer survivors, the presence of 
elevated CRP was not associated with breast cancer diagnosis, which was in 
agreement with the findings of some studies (90, 91). However, other studies 
have reported a significant association between CRP and breast cancer risk (92, 
93).  
The biological mechanisms linking obesity and breast cancer is believed 
to be related to insulin resistance and inflammation, which induce aromatase 
expression and estrogen synthesis (9, 10). Adipose tissue is a major source of 
estrogenic hormones and both aromatase expression and estrogen synthesis are 
linked to increased risk of breast cancer (94). Insulin has a gonadotrophic effect 
and upregulates aromatase activities (95). Additionally, the inflammation pathway 
originates in tissues involved in metabolism: adipose tissue, liver and muscle 
tissues (96). These tissues in response to metabolic stimuli trigger the 
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inflammatory response (93, 96). Inflammatory responses are characterized by an 
increase of cytokines and markers of active inflammation (CRP and fibrinogen).  
While a biological mechanism linking obesity to breast cancer has been 
proposed (9, 10), the non-significant results of this study do not support they 
hypothesis. However, we noted that breast cancer survivors had significantly 
lower measures of blood glucose, blood pressure and triglycerides when 
compared to women without breast cancer. Visceral adiposity is central to the 
definition of MetS because it contributes to hypertension, high serum cholesterol, 
low HDL-cholesterol, and hyperglycemia (97).  However, the mean waist 
circumference of women who had a breast cancer diagnosis did not differ 
significantly from that of women without breast cancer. These findings suggest 
that breast cancer survivors, have similar metabolic characteristics to the general 
population. The prevalence of obesity in this study and as reported elsewhere 
(98) did not differ between women with breast cancer and women without breast 
cancer. Even in another nationally representative sample, no differences were 
shown between survivors (58%) and those without cancer (55%) in overweight 
and obesity status (99) prevalence. However, in sensitivity and a subset analysis 
of obese women in our study, MetS was associated with breast cancer diagnosis 
for women (n=31) who had 10 or more years of survival (OR=5.0, 95% CI: 1.27-
19.33). This perhaps implies that the impact of MetS varies by obesity status and 
the number of survival years. It is important that to note while studies have 
assessed the prevalence of MetS in breast cancer survivors, very few studies 
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included a control group with whom to compare the measures of MetS and CRP 
with. 
Although not significantly different, women who had a breast cancer 
diagnosis had a higher education level compared to those without a cancer 
diagnosis. Higher educational levels have previously been correlated with 
healthier lifestyle factors; lower smoking rates, higher fruit and vegetable intake, 
alcohol consumption and increased physical activity (100). All these factors may 
have a role in reducing the risk from the components of MetS and CRP which are 
highly correlated with BMI. In a case control study, short term breast cancer 
survivors followed multiple behavioral recommendations when they were 
compared to controls; however, long term survivors were less likely to follow the 
recommendations (101). This study supports the results of our sensitivity 
analysis that the association of MetS may in part vary by short and long term 
survival years. Perhaps the experience of cancer diagnosis encouraged cancer 
survivors to modify their lifestyle choices, in addition to constant 
recommendations and close monitoring by their physicians. However, older and 
less educated survivors may be less likely to discuss with their physician health 
promotion interventions (102).  
The study limitations are those inherent in observational studies. A 
limitation of this study design is potential uncontrolled confounding differences 
between those with breast cancer diagnosis and those without breast cancer that 
were not included in the analyses. This study involved women who survived 
breast cancer and therefore, a survival bias may exist. Another limitation is the 
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inability to determine temporal sequence between the risk factors and the 
outcome due to the cross-sectional study design; reverse causation may exist 
since the obesity markers were measured after cancer diagnosis. Although the 
components of MetS and CRP were measured by trained professionals, they are 
based on a single assessment. This study included a modest sample size of 
women with breast cancer, the number was too small to generate an adequate 
distribution in the categories of MetS and CRP. 
Despite these limitations, the results are robust given that we controlled 
for several potential confounders, beyond the demographic factors, that may 
influence the association between MetS, CRP and breast cancer risk. In addition, 
this study included data from a large survey (NHANES) with a nationally 
representative sample. The study also included a modest sized sample of 
women with breast cancer and a large control group. Lastly, the exposure 
variables, components of MetS, including waist circumference, triglycerides, 
HDL-cholesterol, blood glucose and blood pressure were objectively measured, 
therefore removing recall bias.  
The findings of this nationally representative sample suggest that MetS 
and high levels of CRP are prevalent among breast cancer survivors but no 
association was established with being a cancer survivor compared to women 
with no breast cancer diagnosis. Longitudinal studies should be conducted to 
assess the association of Mets and CRP among both early stage and late stage 
breast cancer survivors. It is possible that the association of Mets and CRP with 
breast cancer may vary by the years of survival.  
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Table 2.1 Weighted Demographic and Health Related Characteristics of 
Breast Cancer Survivors and those without Breast cancer  
 Breast 
Cancer 
Survivors 
N=172 
No Breast 
Cancer 
N=2000 
 
 Mean (SD) Mean (SD) p-value 
Age 66.0 (8.3) 61.2 (8.6) <.0001 
Age at menarche 12.7 (1.7) 12.8 (1.7) 0.24 
Age at last menstrual period 46.9 (7.5) 46.4 (7.6) 0.39 
Blood pressure 128.6 (19.6) 131.3 (21.3) 0.74 
Fasting blood glucose 106.4 (28.6) 110.3 (40.4) 0.09 
HDL-Cholesterol 59.8 (17.5) 61.1 (16.9) 0.38 
Triglycerides 117.7 (77.3) 131.3 (90.4) 0.06 
Waist Circumference 98.0 (15.1) 95.9 (14.3) 0.13 
C-reactive protein 0.51 (1.8) 0.47 (0.8) 0.004 
Body Mass Index (BMI)  29.2 (7.4) 28.5 (6.5) 0.28 
    
 n (%) n (%) X² [DF] p-value 
Education    
Less than high school  44 (17.7) 516 (15.3) 3.40 [2] 0.18 
High school graduate 37 (17.2) 550 (30.1)  
College education 91 (65.1) 934 (54.6)  
Race    
Non-Hispanic White 91 (88.8) 1064 (79.0) 11.95 [2] 0.001 
Non-Hispanic Black 22 (6.6) 403 (9.6)  
Others 18 (4.6) 533 (11.4)  
Marital Status    
Married/Have partner 100 (65.8) 1094 (62.7) 0.76 [1] 0.38 
Not married 72 (34.2) 906 (37.3)  
Smoked at least 100 cigarettes in life 
Never 96 (58.6) 1171 (57.0) 11.95 [2] 0.003 
Past Smoker 57 (29.7) 509 (27.2)  
Current Smoker 19 (11.8) 319 (15.8)  
Had at least 12 drinks/year    
Yes 101 (66.1) 1065 (64.1) 1.61 [1] 0.21 
No 59 (33.9) 772 (35.9)  
Use of Hormones    
Yes 64 (42.4) 756 (45.0) 0.08 [1] 0.78 
No 95 (57.6) 1071 (55.0)  
Metabolic Syndrome     
Yes  52 (42.6) 690 (44.2) 0.11 [1] 0.74 
No 70 (57.4) 871 (55.8)  
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Table 2.2 Odds Ratios (OR) with 95% Confidence Intervals (CI) for 
Breast Cancer according to Components of Metabolic Syndrome in 
the National Health and Nutrition Examination Survey, 1988-2006 
  No. of Cases 
n=172 
OR (95% CI)a OR (95% CI)b 
 
Waist Circumference    
Low risk (<88 cm) 41 Reference Reference 
High risk (≥88 cm) 121 1.01 (0.64-1.61) 1.29 (0.82-2.04) 
Systolic Blood Pressure     
Low risk (<130 mm 
Hg) 
80 Reference Reference 
High risk (≥130 mm 
Hg) 
77 0.62 (0.42-0.91) 0.65 (0.43-1.01) 
Triglycerides     
Low risk (<200 mg/dl) 124 Reference Reference 
High risk (≥ 200 
mg/dl) 
28 0.61 (0.37-1.02) 0.72 (0.37-1.46) 
HDL-cholesterol    
Low risk (≥50 mg/dl) 103 Reference Reference 
High risk (<50 mg/dl) 50 1.01 (0.65-1.57) 1.19 (0.74-1.91) 
Blood Glucose     
Low risk (<100 mg/dl) 75 Reference Reference 
High risk (≥100 
mg/dl) 
78 1.03 (0.69-1.55) 0.89 (0.58-1.36) 
aAdjusted for age (continuous) and race/ethnicity. b Adjusted for  age 
(continuous), race/ethnicity (non-Hispanic White, non-Hispanic Black, and 
Others), education (less than high school education, high school graduate 
and college education), marital status (married or living with partner 
Yes/No), age at menarche (continuous), age at menopause (continuous), 
smoking (never, current and past), alcohol intake (number of drinks/year) 
and hormone use (Yes/No). 
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Table 2.3 Odds Ratios (OR) with 95% Confidence Intervals (CI) for 
Breast Cancer according to Metabolic Syndrome and C-Reactive 
Protein in the National Health and Nutrition Examination Survey 
  No. of 
Cases 
n=172 
OR (95% CI)a OR (95% CI)b 
 
C-Reactive protein     
Low risk (<1.0 mg/dl) 143 Reference Reference 
High risk (≥ 1.0 mg/dl) 29 1.01 (0.46-2.21) 1.04 (0.45-2.42) 
    
Presence of metabolic syndrome 
No 100 Reference Reference 
Yes 72 0.79 (0.47-1.33) 0.92 (0.53-1.60) 
No. of abnormal metabolic syndrome components 
0-2 100 Reference Reference 
3 52 1.03 (0.62-1.72) 1.09 (0.65-1.84) 
4 and 5 20 0.59 (0.26-0.98) 0.57 (0.29-1.12) 
    
aAdjusted for age (continuous) and race/ethnicity. b Adjusted for  age 
(continuous), race/ethnicity (non-Hispanic White, non-Hispanic Black, 
and Others), education (less than high school education, high school 
graduate and college education), marital status (married or living with 
partner Yes/No), age at menarche (continuous), age at menopause 
(continuous), smoking (never, current and past), alcohol intake (number 
of drinks/year) and hormone use (Yes/No). 
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Table 2.4 Odds Ratios (OR) with 95% Confidence Intervals (CI) of 
Joint association for Metabolic Syndrome and C-Reactive Protein in 
relation to Breast Cancer status 
  
No. of 
Cases 
n=172 
OR (95% CI)a OR (95% CI)b 
 
Mets and CRP risk    
No Mets + No elevated CRP 60 Reference Reference 
No Mets + elevated CRP 10 0.69 (0.26-1.84) 0.69 (0.24-2.02) 
Mets + No elevated CRP 45 0.77 (0.47-1.27) 0.85 (0.51-1.42) 
Mets + Elevated CRP 7 0.89 (0.28-2.83) 0.92 (0.29-2.96) 
aAdjusted for age (continuous) and race/ethnicity. b Adjusted for  age 
(continuous), race/ethnicity (non-Hispanic White, non-Hispanic Black, and 
Others), education (less than high school education, high school graduate 
and college education), marital status (married or living with partner 
Yes/No), age at menarche (continuous), age at menopause (continuous), 
smoking (never, current and past), alcohol intake (number of drinks/year) 
and hormone use (Yes/No). 
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CHAPTER 3: METABOLIC SYNDROME AND CANCER MORTALITY IN 
WOMEN 
Abstract  
Objective: Metabolic syndrome (MetS) is an important prognostic factor for the 
occurrence of cancer. However, little is known about the association of MetS and 
cancer mortality in women. The purpose of this study was to evaluate whether 
MetS and its components are associated with risk of obesity-related cancer 
mortality. We also sought to evaluate if the association of MetS and cancer 
mortality differed by levels of C-reactive protein (CRP).  
Methods: A total of 140 deaths from obesity-related cancers (breast, colorectal 
and endometrial) linked through the National Death Index, were identified from 
10,103 eligible subjects aged ≥18 years. The exposure variables were MetS and 
CRP. Cox proportional hazards regression, adjusted for confounders, was used 
to estimate hazard ratios (HR) with 95% confidence intervals (CI) for cancer 
mortality in relation to MetS, the components of MetS, and CRP.  
Results: Overall, MetS was associated with increased risk of mortality from 
obesity-related cancers. The mortality HR from obesity-related cancer was 2.33 
(95% CI: 1.02-5.33) for women with the most severe MetS (all 5 components 
abnormal) compared to those without MetS. MetS was not associated with site-
specific (breast and colorectal) cancer mortality. All components of MetS, except 
dyslipidemia, were associated with increased risk of mortality for obesity-related 
cancers and breast cancer. There was a greater than two-fold increased risk for 
mortality from obesity-related cancers for women with enlarged waist 
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circumference [HR=2.23, 1.10-4.42, quartile (Q) 4 vs. Q1,], and high systolic 
blood pressure [HR=2.69, 1.08-6.71, Q4 vs. Q1, p-trend=0.0085] and blood 
glucose [HR=2.5, 1.20-5.32, Q2 vs.  Q1]. Women with CRP ≥ 1.0 mg/dl 
compared to those with CRP <1.0 mg/dl had an increased risk of mortality from 
obesity-related cancers [HR=2.64, 1.53-4.66] as well as breast and colorectal 
cancer mortality. When joint MetS and CRP association was assessed, women 
with low CRP (<1.0mg/dl) levels and with 5 abnormal components of MetS had a 
significantly higher risk of mortality from obesity related cancers compared to 
those without MetS (HR=3.47; 95% CI: 1.34-8.98). 
Conclusion: C-reactive protein and metabolic syndrome are associated with 
obesity-related cancer mortality in women.  
Key words: Obesity, Metabolic syndrome, C - reactive protein, cancer mortality, 
breast cancer, colorectal cancer, cohort study, and epidemiology   
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Introduction 
Breast, colorectal and endometrial cancers are three of the 5 most 
common cancers among women in the US ranking first, third and fourth 
respectively (103). In 2015 it was estimated that among women, these would 
account for 810,170 new cancer cases and 277,280 cancer deaths (103). These 
three cancers account for 44% of all new cancer cases and 28% of all cancer 
deaths among women in the U.S. (103). One factor shown to be related to the 
development of breast (104-106), colorectal (49, 107) and endometrial (108) 
cancers is obesity.  
Obesity has reached epidemic proportions in the developed countries (16, 
109). In the U.S., more than one third (37%) of adult women are obese and 30% 
overweight (110). It is estimated that if the current trends continue 50% of women 
in the US will be obese by the year 2020 and 58% by 2030 (111). Obesity is the 
major determinant of MetS (1, 31) which is a growing problem in Western 
populations, with a prevalence of approximately 25% in the U.S.(27, 28). 
According to the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III), MetS for women is defined as a cluster of at least 
three or more of the following five factors: high-density lipoprotein (HDL) 
cholesterol (<50 mg/dl), triglycerides (≥ 50 mg/dl), systolic blood pressure (≥ 130 
mm Hg), blood glucose (≥100 mg/d) and waist circumference (≥ 88 cm) (29, 31). 
MetS and CRP have been shown to be related (112) and CRP has previously 
been suggested as a component of the MetS (73). 
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The prognostic use of Mets (36, 113, 114) and CRP (115) has been 
demonstrated in breast, colorectal and endometrial cancer. However, no studies 
to our knowledge have assessed both MetS and CRP levels and their 
association with risk of cancer mortality. We therefore sought to evaluate the 
possible interrelationships between MetS, CRP and obesity-related cancer 
mortality (breast, colorectal and endometrial) among participants in the Third 
National Health and Nutrition Examination Survey (NHANES III). Additionally, we 
sought to find out if CRP modified the association of the MetS with obesity-
related cancer mortality. 
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Materials and Methods 
Sample Design 
This study is based on data collected from the NHANES III (1988-1994). 
NHANES III was conducted by the U.S. National Center for Health Statistics 
(NCHS) of the Centers for Disease Control and Prevention (CDC). The survey 
design and methodology of the NHANES III have previously been described in 
detail elsewhere (77). In brief, NHANES III uses a stratified, multistage probability 
design. Low income individuals, older persons, African Americans and Mexican 
Americans were oversampled to provide adequate numbers of these groups in 
the study. This increases the reliability and precision of estimates for these 
population subgroups.  Using sampling and weighting, the NHANES estimates 
are considered generalizable to the US population. The NCHS Institutional 
Review Board approved the survey protocols and informed consent was obtained 
from all subjects. Since this study involved secondary data analysis of publicly 
available data and the data were de-identified, this study was determined by the 
Indiana University IRB as exempt from review.  
 
Study population 
This study focused on 10,103 women aged 18 years or older who 
participated in NHANES III and were followed up.  A total of 322 pregnant women 
were excluded because of increased waist circumference and potential metabolic 
changes during pregnancy. Of the 9,781 remaining subjects, 140 deaths from 
obesity-related cancers (including 80 breast, 46 colorectal and 14 endometrial) 
55 
were identified during the follow-up period of 133,032 person-years. The follow-
up period for each of the subjects was calculated as the time from the date of 
health examination to the occurrence of cancer death or the censor date 
(December 31, 2006), whichever occurred first. 
Data Collection 
Mortality data for each of the participants was ascertained by probabilistic 
match between NHANES III database and the death certificate records of the 
U.S. National Death Index (77). Obesity-related cancer mortality included deaths 
from endometrial, breast and colorectal cancer mortality as defined by the 9th 
revision of the International Classification of Diseases (ICD). Endometrial cancer 
mortality refers to cancers coded as mortality occurring from malignant 
neoplasms of corpus uteri and uterus (ICD-9-CM Diagnosis Code 180). The ICD 
codes for breast and colorectal cancer were ICD-9-CM 174 and ICD-9-CM 153 
respectively.  
The NHANES III database included the results of standardized household 
interviews followed by an extensive physical and health examinations were 
conducted at a mobile examination center. During the home interview, 
demographic, socioeconomic, and anthropometric characteristics, medical 
conditions, and medications used were collected. The NHANES III included 
components of MetS: blood pressure, blood glucose, waist circumference, 
triglycerides, and HDL-cholesterol, which were measured during the physical 
examination. Systolic blood pressure (mmHg) was measured using a mercury 
sphygmomanometer while subjects were in a seated position. Three 
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measurements were taken and then averaged for each subject to minimize 
measurement error (78). Fasting blood samples were drawn by a trained 
phlebotomist.  Serum concentrations of HDL-cholesterol and triglycerides were 
measured enzymatically with Hitachi 704 Analyzer, while serum levels of glucose 
was determined using the glucose hexokinase method with Hitachi 737 Analyzer 
(78). Waist circumference was determined at the iliac crest after a normal 
exhalation of breath (78). High sensitivity CRP concentration was quantified 
using latex-enhanced nephelometry, and reported in mg/dl to the nearest 
hundredth (0.01) (78). 
Statistical Analysis 
Descriptive statistics were calculated to show the characteristics of study 
participants by severity of MetS. Pearson chi-square tests and analysis of 
variance were performed to compare the distributions of covariates and 
exposures of interest (components of MetS and CRP). Cox proportional hazards 
regression was used to estimate the hazard ratios (HR) and 95% confidence 
intervals (CI) for obesity-related cancer mortality in relation to each of individual 
MetS components and the composite score. Site-specific (breast and colorectal) 
HR were also assessed; there were too few endometrial cancer deaths to 
perform a specific analysis for that site. For the individual components of MetS, 
the HRs and 95% CIs were calculated with subjects in the lowest quartile used 
as the reference group. Tests for linear trend across quartiles were performed by 
including ordinal variables in the models using the median value of each quartile. 
A composite score of MetS was created; for each individual component, a score 
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of 0 was assigned if the level of each component was within normal range and a 
score of 1 was assigned if the component was abnormal. A score of 0 was 
assigned for waist circumference <88 cm, systolic blood pressure <130 mg/dl, 
blood glucose <100 mg/dl, triglycerides <150mg/dl and HDL-cholesterol 
>50mg/dl. The composite score ranged 0-5, with 0 indicating no abnormal MetS 
components and 1 to 5 representing the presence of 1 to 5 abnormal 
components, respectively. Based on the diagnostic criteria of MetS, subjects with 
a composite score of 3 or more were classified as having metabolic disorder.  
The potential confounders were largely based on their relevance to MetS 
and cancer risk (28). The variables were adjusted as confounders in the 
regression models if they altered parameter estimates for the primary exposure 
variables of interest by 10% or more or had a p-value (<0.25) for their regression 
coefficients (116). The multivariable models were adjusted for age (years), 
race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and other), 
education (less than high school, high school, college and graduate education), 
cigarette smoking (never, former, and current), alcohol intake (yes/no), and use 
of insulin (or diabetes), hypertension, and cholesterol-lowering medications (yes 
or no for each of the medications). 
To assess the effect of CRP on the association of MetS and obesity-
related cancers mortality, CRP, MetS and the interaction term were included in 
the multivariable Cox proportional hazard regression model. The effect of CRP 
on the association of MetS and specific colorectal cancer mortality was not tested 
because of the small number of colorectal cancer deaths and the multiple levels 
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of severity of the MetS. A weight variable was included in all analytical 
procedures to account for complex survey design, survey non-response, and 
post-stratification (117). P-values of <0.05 were considered statistically significant 
and all statistical analyses were conducted using SAS (version 9.3).  
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Results 
A total of 2,447 (31.3%) women respondents met the NCEP criteria for 
MetS. The distributions of demographic factors and values for the components 
MetS of those with and those without the syndrome in the study population are 
shown in Table 3.1. Women with all 5 abnormal components were more often 
non-Hispanic white and were older, with a mean age 65.5 (±12). Additionally, 
women with all 5 components had lower education levels and higher smoking 
rates compared to those without MetS. More of the women without MetS had a 
college education or greater compared to women with all 5 components of MetS 
(43% vs. 22%).  
Results for the association of individual components of MetS with risk of 
obesity-related cancer mortality in women and sub-site cancers are presented in 
Table 3.2. All components of MetS except triglycerides and HDL-cholesterol were 
associated with total and breast cancer mortality. Women with waist 
circumferences greater than 102.2 cm (Quartile 4) had increased hazard for 
obesity-related cancers mortality and breast cancer mortality which had a 
significant p-trend (p-trend=0.009) when compared to those with less than 82 cm 
(Quartile 1). Additionally, having an increased systolic blood pressure (≥137 
mg/dl) or a blood glucose of 86 to 92 mg/dl was associated with greater than two-
fold increased hazard for both total and breast cancer mortality when compared 
to those in the lowest quartile. An elevated CRP (>1.0 mg/dl) was associated with 
increased risk of obesity-related cancers mortality as well as site-specific breast 
and colorectal cancer mortality.  
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Table 3.3 shows the hazard ratios of obesity-related cancer mortality in 
relation to MetS and severity of MetS. In adjusted models MetS was not 
associated with obesity-related cancer, breast or colorectal cancer mortality. 
However, when mortality was assessed for each of the 3 high risk levels (having 
3, 4 or 5 components), women with all 5 abnormal components had increased 
hazard for obesity-related cancer mortality (HR=2.33; 95% CI: 1.02-5.33) when 
compared to women with no MetS. Of note, the risk of breast cancer mortality 
increased with an increasing number of abnormal MetS components, although 
this trend was not statistically significant. Women with the most severe MetS (all 
5 components abnormal) had a non-significant three fold and two fold increased 
hazard for breast and colorectal cancer mortality respectively compared to 
women with no MetS. 
The second research question explored the relationship of MetS and 
cancer mortality by CRP levels. The a priori specified interaction of MetS and 
CRP was significant (p-value=0.02) and the results indicate that the association 
of MetS and obesity-related cancers was restricted to women with a CRP of 
<1.00 mg/dl. As shown in Table 3.4, women with a CRP of <1.00 mg/dl and with 
5 abnormal components had a three-fold increased hazard for obesity-related 
cancer mortality (HR=3.47; 95% CI: 1.34-8.98) when compared to women with 
no MetS. In contrast, the hazard for obesity-related cancer mortality among 
women with a CRP of ≥1.00 mg/dl and with 5 abnormal components was clearly 
non-significant with a 95% CI that markedly spanned both sides of the null value 
of 1.0 (0.13-2.95). The MetS and CRP interaction with breast cancer mortality 
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was not significant (p-value=0.0533); women with a CRP <1.00 mg/dl and 3 or 5 
abnormal components had a non-significant increased hazard for breast cancer 
mortality.  
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Discussion 
This study examining MetS and CRP suggests that the severity of MetS is 
associated with an increased risk of obesity-related cancer mortality. This 
association was stronger among women with low levels of CRP. All individual 
components of MetS, except triglycerides and HDL-cholesterol, were significantly 
associated with risk of mortality from obesity-related cancer and breast cancer. 
Though not significant, the risk for breast cancer mortality increased with an 
increasing number of abnormal MetS components. Having a high CRP level was 
significantly associated with increased risk for obesity-related cancers, breast 
and colorectal cancer mortality.  
Few studies have examined MetS or the individual components in relation 
to breast (118, 119) and colorectal (120, 121) cancer mortality. Lee et.al 
assessed total (all sites) cancer mortality in women and similar to our study they 
did not find an association with MetS and risk of cancer mortality when compared 
to women without MetS (122). However, while our study found significant 
associations with individual components of Mets (waist circumference, blood 
pressure, and blood glucose) and risk of obesity-related cancer mortality, Lee et 
al. only found blood pressure to be significantly associated with total cancer 
mortality. Additionally, elevated blood pressure in women has been associated 
with total cancer mortality in a previous study (123). While the two studies 
assessed total cancer mortality in women, our study focused on only mortality 
from cancers that have strongly been linked to obesity; thus, this in addition to 
our sample size, may contribute to the conflicting results. 
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In our study, CRP was associated with increased risk of obesity-related 
cancer mortality, breast cancer and colorectal cancer mortality in women. To our 
knowledge, very few studies have examined the association of CRP and obesity 
related cancer mortality. In one study, total cancer mortality in women was not 
associated with CRP [HR=1.24; 95% CI: 0.75-2.06] (124). However, site-specific 
assessments have shown that women with an elevated CRP were found to have 
a greater risk of colorectal cancer death when compared to those with lower 
levels (125, 126).    
The effect of CRP on the association of MetS and cancer mortality has not 
been explored previously. In our study, CRP is correlated with all the 
components of the metabolic syndrome (data not shown) and the strongest 
correlation observed with CRP and waist circumference (r=0.25, p <.0001). In a 
population based study, positive correlations were reported for all components of 
the MetS, except with HDL-cholesterol which showed an inverse correlation 
(112). Our study showed that the association of MetS and obesity-related cancer 
mortality was stronger for women with a low-CRP level. However, no clear 
explanation exists on this effect, other than CRP has been shown to be an 
independent prognostic marker for other chronic diseases (73). CRP levels have 
also been previously associated with cancer risk (127). Perhaps the synergistic 
effect seen in our study indicates that CRP may be an important prognostic factor 
for obesity-related cancers, in addition to the MetS. 
Breast Cancer Mortality. Several studies have shown that obesity is 
associated with increased risk of breast cancer mortality (128-131). However, to 
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our knowledge there are limited studies that have assessed MetS and risk of 
breast cancer mortality (118, 119). Previous studies have demonstrated that 
women with MetS had an increased risk of breast cancer mortality compared to 
those who did not (118, 132). Our study found an increased but not significant 
association of MetS with risk of breast cancer mortality. This non-significant 
association may be attributed to the small number of cases of breast cancer 
mortality in our study.  
The components of MetS have also been associated with breast cancer 
mortality but the results are inconsistent. Our findings that elevated blood 
pressure and blood glucose levels increase breast cancer mortality are 
supported by two other cohort studies (118, 119) but another study found no 
association (132). This study and others (118, 119, 132) did not show an 
association of triglycerides and HDL-cholesterol with breast cancer mortality. 
There are different criteria for characterizing MetS, while our study used waist 
circumference as a measure of central obesity other studies used BMI or weight 
as a measure of central obesity (118, 119, 132). Regardless of the measure, BMI 
or waist circumference, the results are consistent that central obesity is 
associated with increased risk of breast cancer mortality. 
Colorectal Cancer Mortality. Several studies have assessed obesity and 
colorectal cancer mortality (133, 134). To the best of our knowledge no studies 
have assessed MetS and colorectal cancer mortality. Although we conducted 
data analysis on the association of MetS with colorectal cancer mortality in 
women, these results should be interpreted with caution since only a small 
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number (n=46) of colorectal deaths were recorded. However, even with a small 
sample, women with elevated blood pressures had a non-significant but 
increased cancer mortality compared to those with lower blood pressure values.   
Endometrial Cancer Mortality. We did not conduct site-specific hazard 
statistics for endometrial cancer because of the small number of deaths. 
However, it is important to note that obesity is one of the strongest risk factors for 
endometrial cancer (135). Furthermore, the components of the MetS have 
independently been associated with risk for endometrial cancer (114, 136). In a 
SEER–Medicare linked case control study, the risk estimates were: 
overweight/obesity, fasting glucose, high blood pressure, and high triglycerides 
(136). However, low HDL-cholesterol has not been associated with risk of 
endometrial cancer (114, 136). 
There are some potential biological mechanisms by which MetS 
modulates cancer risk. The link between obesity and cancer is believed to be 
related to endogenous estrogen, insulin resistance and inflammation (9, 10, 38). 
Visceral obesity has been shown to be associated with insulin resistance and 
elevated insulin-like growth factor 1 (IGF-1) (32, 137). Insulin resistance, a 
component of the MetS, is the best established pathway linking obesity and 
colorectal cancer (38). Adipose tissue is an important source of estrogen (94) 
and estrogen induces proliferation of endometrial and breast (post-menopausal) 
cancer cells (138, 139).  Considering that insulin, IGF-1, and estrogen have been 
identified as risk factors for obesity-related cancers (breast, colorectal and 
endometrial), perhaps it is plausible that obesity promotes cancer cell 
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proliferation at least in part through obesity-initiated MetS. Inflammatory 
responses are characterized by an increase of cytokines and markers of active 
inflammation (CRP and fibrinogen). The acute-phase CRP is an inflammatory cell 
compound that has been associated with diabetes mellitus (140). There is 
growing evidence that CRP is associated with risk of cancer, especially obesity-
related cancers (141-143).  
A key strength in our study is that the data were based on a national 
representative sample of the U.S. population. The study included a large number 
of women therefore allowing us to test and adjust for potential confounders 
appropriately for the associations of interest. Recall bias was minimized in the 
study; all five anthropometric, physiological, and biochemical components of 
MetS were objectively measured with validated assessment tools or experimental 
methods.  More importantly, MetS as a whole, its individual components, and 
their combinations were evaluated in relation to the risk of obesity-related and 
breast cancer mortality in our study. Unlike previous studies, our study focused 
primarily on cancers that have been associated with obesity. There is strong 
evidence that breast, colorectal and endometrial cancers are associated with 
obesity. 
Some limitations exist in the present study. The components of MetS were 
measured only once, and therefore the effect of changes in these risk factors 
over time on obesity-related cancer mortality could not be evaluated. While the 
study has a large number of women overall, the smaller number of deaths from 
colorectal and endometrial cancers limits the ability to compare severity levels of 
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MetS with confidence.  CRP, MetS and its components in relation to endometrial 
cancer were not examined due to small sample size and low statistical power.  
However, we had 96% and 91% statistical power to assess the association of 
Mets with obesity-related cancers and breast cancer mortality, respectively. As in 
other observational studies, it is possible that residual confounding due to 
unmeasured confounders might have somewhat distorted the results obtained 
from the present study.  
In summary, severe MetS, the components of MetS and CRP appear to 
be associated with mortality of obesity-related cancers in women. The findings of 
the present study offer novel evidence for the potential role of MetS, CRP and 
their interaction in carcinogenesis and mechanistic data for the associations 
between obesity and cancer risk. If the results of this study are confirmed in other 
observational studies, especially prospective cohort studies, the importance of 
maintaining healthy levels of the components of the MetS and CRP would be 
accentuated. This would perhaps result in a reduction in cancer mortality in 
women. 
 
  
 
  
Table 3.1 Baseline characteristics of participants by the number of abnormal metabolic syndrome 
components in the Third National Health and Nutrition Examination Survey, 1988-1994 
  No. of abnormal metabolic syndrome components 
 0-2 
(n=5,367) 
3  
(n=1,308) 
4 
(n=803) 
5 
(n=336) 
 
 Mean (SD) F value, p-value 
Age (year) 41.68 (18.3) 53.62 (18.1) 61.06 (15.3) 65.47 (12.4) 511.0, <.0001 
Waist circumference (cm) 85.79 (13.5) 100.16 (12.1) 103.76 (13.3) 105.21 (10.9) 870.2, <.0001 
Serum triglycerides (mg/dl) 98.90 (51.7) 171.13 (102.7) 220.00 (112.7) 285.99 (149.4) 1254.4, <.0001 
HDL-cholesterol (mg/dl) 58.22 (15.2) 48.82 (13.8) 44.36 (11.5) 39.67 (6.9) 440.7, <.0001 
Systolic blood pressure (mmHg) 116.67 (17.4) 132.93 (21.6) 140.43 (20.0) 149.22 (15.3) 806.0, <.0001 
Serum glucose (mg/dl) 89.19 (17.9) 108.22 (46.2) 126.17 (59.5) 157.33 (73.0) 673.8, <.0001 
C-Reactive Protein (mg/DL) 0.43 (0.72) 0.63 (0.8) 0.77 (1.3) 0.76 (0.9) 61.1, <.0001 
 
N (%) X² [DF], p-value 
Race   
   Non-Hispanic White 2200 (75.55) 544 (75.00) 368 (75.16) 180 (83.31) 17.66 [9], 0.07 
   Non-Hispanic Black 1601 (11.57) 347 (12.04) 178 (11.04) 53 (7.86)  
   Hispanic 1318 (4.52) 362 (6.08) 226 (5.71) 95 (4.52)  
   Other race 248 (8.36) 55 (6.89) 31 (8.09) 8 (4.31)  
Education     
   Less than High school 893 (8.14) 351 (16.39) 275 (18.23) 127 (17.42) 262.96 [9], <.0001 
   High school education 2736 (48.47) 675 (54.78) 392 (60.17) 157 (60.29)  
   College education 1423 (35.20) 229 (23.70) 113 (19.37) 43 (18.28)  
   Graduate education 287 (8.19) 48 (5.13) 20 (2.23) 9 (4.00)  
Cigarette Smoking     
   Never 3340 (55.64) 765 (49.29) 509 (56.69) 220 (59.20) 92.85 [6], <.0001 
   Former  1215 (26.36) 283 (27.86) 124 (16.20) 41 (11.61)  
   Current 812 (18.00) 260 (22.85) 170 (27.10) 75 (29.19)  
Alcohol Intake      
Yes 2329 (52.62) 388 (37.71) 187 (27.03) 56 (21.64) 269.56 [3], <.0001 
No 3038 (47.38) 920 (62.29) 616 (72.97) 280 (78.36)  
Percentages were calculated using sample weights to report estimates that would be representative of the U.S. population. 
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Table 3.2 Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Cancer Mortality according to 
Quartiles of Components of Metabolic Syndrome and C-Reactive Protein in the National Health and 
Nutrition Examination Survey, 1988-2006 
 
Obesity-Related Cancers 
Mortality 
b Breast Cancer Mortality b Colorectal Cancer Mortality 
 
No. of 
Cases 
n=140 
HR (95% CI)a 
No. of 
Cases 
n=80 
HR (95% CI)a 
No. of 
Cases 
n=46 
HR (95% CI)b 
Waist Circumference (cm)       
Q1 (<82 ) 18 Reference 6 Reference 9 Reference 
Q2 (82-92.1) 25 1.29 (0.62-2.67) 12 1.28 (0.62-2.66) 11 0.46 (0.17-1.27) 
Q3 (92.2-102.1) 19 0.91 (0.40-2.10) 16 0.91 (0.39-2.09) 2 0.15 (0.03-0.70) 
Q4 (≥102.2) 41 2.23 (1.10-4.52) 25 2.24 (1.11-4.55) 11 0.79 (0.30-2.11) 
p-trend  0.20  .001  0.12 
Systolic Blood Pressure       
Q1 (<111) 18 Reference 14 Reference 
13 
Reference 
(<137 mmHg) 
Q2 (112-121) 10 0.83 (0.31-2.22) 8 0.83 (0.31-2.22) 
Q3 (122-136) 25 2.03 (0.88-4.72) 14 2.03 (0.87-4.71) 
Q4 (≥137) 56 2.69 (1.08-6.71) 25 2.69 (1.08-6.72) 24 2.08 (0.87-4.97) 
p-trend  
0.009 
 
0.41 
 0.007 
Triglycerides (mg/dl)       
Q1 (<78) 18 Reference 10 Reference 6 Reference 
Q2 (79-102) 27 1.74 (0.81-3.75) 17 1.74 (0.48-1.97) 7 2.53 (0.58-10.95) 
Q3 (113-169) 32 1.45 (0.66-3.18) 18 1.44 (0.66-3.17) 10 1.94 (0.45-8.31) 
Q4 (≥170) 26 1.21 (0.52-2.83) 14 1.20 (0.51-2.81) 11 1.73 (0.38-7.86) 
p-trend  0.27  .37  0.93 
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Obesity-Related Cancers 
Mortality 
b Breast Cancer Mortality b Colorectal Cancer Mortality 
HDL-cholesterol (mg/dl)       
Q1 (<40) 19 Reference 12 Reference 6 Reference 
Q2 (41-48) 21 0.90 (0.43-1.88) 15 0.89 (0.35-2.26) 6 1.08 (0.30-3.97) 
Q3 (49-59) 23 0.49 (0.22-1.08) 14 0.39 (0.14-1.13) 5 0.39 (0.08-1.81) 
Q4 (≥60) 40 1.00 (0.51-1.97) 18 0.73 (0.30-1.81) 17 1.42 (0.45-4.47) 
p-trend  0.67  0.82  0.34 
 
Blood Glucose (mg/dl) 
 
 
 
 
  
Q1 (<85) 14 Reference 8 Reference 6 Reference 
Q2 (86-92) 24 2.53 (1.20-5.32) 15 2.53 (1.20-5.32) 6 2.31 (0.65-8.21) 
Q3 (93-101) 24 1.04 (0.43-2.52) 13 1.04 (0.43-2.52) 8 0.94 (0.22-3.93) 
Q4 (≥102) 37 1.83 (0.80-4.19) 20 1.83 (0.80-4.21) 13 1.46 (0.38-5.66) 
p-trend  0.12  0.14  0.96 
*C-Reactive protein 
(mg/dl) 
      
< 1 mg/dl 81 Reference 47 Reference 26 Reference 
≥ 1mg/dl 20 2.64 (1.53-4.66) 11 2.53 (1.15-5.58) 7 2.93 (1.28-6.71) 
a Adjusted for age (years), race (non-Hispanic white, non-Hispanic black, Mexican American, and other race), 
education (no education, less than high school, high school, college and graduate education), cigarette 
smoking (current, former, and never), alcohol intake (yes or no), and use of insulin or diabetes, hypertension, 
and cholesterol-lowering medications (yes or no for each of the medications). Because of the number of breast 
and colorectal cancer deaths, the number of variables in the model was reduced: b Models adjusted for age 
(years), race (non-Hispanic white, non-Hispanic black, Mexican American, and other race) and cigarette 
smoking (current, former, and never). *The median and 25 percentile for CRP were equal at 0.2 therefore we 
used the clinical significance cutoff points. 
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Table 3.3 Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Cancer Mortality  by the 
Components of Metabolic Syndrome 
 Obesity-Related Cancers Mortality Breast Cancer Mortality  Colorectal  Cancer Mortality 
 
 n (%)  HR  (95% CI)a 
 n (%) 
Cases 
 HR  (95% CI) a 
 n (%) 
Cases 
 HR  (95% CI) b 
Presence of Metabolic Syndrome 
No 49 (53.26) Reference 27 (51.92) Reference 16 (53.33) Reference 
Yes 43 (46.64) 1.19 (0.72-1.98) 25 (48.08) 1.77 (0.87-3.60) 14 (46.67) 0.77 (0.35-1.71) 
No. of metabolic syndrome components 
0-2 49 (53.26) Reference 27 (51.92) Reference 16 (53.33) Reference 
3 19 (20.65) 1.17 (0.87-3.60) 12 (23.08) 1.68 (0.75-3.77) 5 (16.67) 0.73 (0.26-2.03) 
4 12 (13.04) 0.83 (0.36-1.91) 8 (15.36) 1.66 (0.57-4.83) 3 (10.00) 0.23 (0.03-1.55) 
5 12 (13.04) 2.33 (1.02-5.33) 5 (9.62) 
2.85 (0.76-
10.67) 
6 (20.00) 2.06 (0.72-5.86) 
a Adjusted for age (years), race (non-Hispanic white, non-Hispanic black, Mexican American, and other race), 
education (no education, less than high school, high school, college and graduate education), cigarette 
smoking (current, former, and never), alcohol intake (yes or no), and use of insulin or diabetes, hypertension, 
and cholesterol-lowering medications (yes or no for each of the medications). b Models were adjusted for age 
(years), race (non-Hispanic white, non-Hispanic black, Mexican American, and other race) and cigarette 
smoking (current, former, and never). 
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Table 3.4 Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Cancer Mortality  by the 
Components of Metabolic Syndrome Stratified by C-Reactive Protein 
 Obesity-related Cancers Mortality Breast Cancer Mortality  
 
 C-Reactive 
protein 
<1.00mg/dl 
  C-Reactive 
protein ≥1.00mg/dl 
 C-Reactive 
protein <1.00mg/dl 
  C-Reactive 
protein 
≥1.00mg/dl 
No. of metabolic syndrome 
components 
    
0-2 Reference Reference Reference Reference 
3 1.51 (0.78-2.91) 0.30 (0.06-1.37) 2.02 (0.87-4.71) 0.07 (0.00-15.32) 
4 0.35 (0.08-.58) 0.98 (0.34-2.83) 0.56 (0.08-3.92) 2.53 (0.56-11.52) 
5 3.47 (1.34-8.98) 0.62 (0.13-2.95) 2.24 (0.38-13.14) 2.13 (0.29-15.73) 
a Adjusted for age (years), race (non-Hispanic white, non-Hispanic black, Mexican American, and other 
race), education (no education, less than high school, high school, college and graduate education), 
cigarette smoking (current, former, and never), alcohol intake (yes or no), and use of insulin or 
diabetes, hypertension, and cholesterol-lowering medications (yes or no for each of the medications). 
bModels were adjusted for age (years), race (non-Hispanic white, non-Hispanic black, Mexican 
American, and other race) and cigarette smoking (current, former, and never). The p-values for the 
interactions were: Obesity-related cancers mortality- MetS*C-Reactive protein, p-value=0.0244 and 
Breast cancer mortality-MetS*C-Reactive protein, p-value=0.0533 
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CONCLUSION 
Findings from the three studies provide important insights into the role of 
obesity, obesity markers on breast and colorectal cancer occurrence and 
mortality. A positive association of waist circumference and BMI in early adult life 
(age 21), with risk of advanced colorectal neoplasia was observed. In addition, 
we also observed that the association of both BMI and waist circumference 
change increased the risk of AN. Metabolic syndrome (MetS) and C-reactive 
protein (CRP) are a growing public health problem because they are directly 
linked to obesity, which is a known risk factor for several chronic diseases 
including some types of cancer. Findings from this study indicated that the 
prevalence of MetS among women with breast cancer does not differ significantly 
from the prevalence among healthy women based on a nationally representative 
sample in the US. However, MetS and CRP were associated with increased risk 
of obesity-related cancer mortality among women. This association was stronger 
among women with low levels (<1 mg/dl) of CRP. All individual components of 
MetS, except triglycerides and HDL-cholesterol, were significantly associated 
with risk of mortality from obesity-related cancer and breast cancer.  
The findings of this dissertation research are novel because there are 
limited studies that have examined these associations. BMI change has been 
explored in relation to colorectal cancer but not in relation to AN, the combination 
of colorectal cancer (CRC) and advanced precancerous polyps. There are very 
limited studies that have assessed WC change with any chronic diseases let 
alone cancer, yet, WC has been shown to be a better measure of visceral 
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adiposity. Studies focusing on MetS and CRP in relation to cancer remain 
scarce. The few studies that have examined MetS and CRP with colorectal and 
cancer have focused on risk prior to diagnosis of the cancers. This dissertation 
examined MetS and CRP among breast cancer survivors who may be at risk of 
recurrence as a result of obesity and obesity related markers. Overall, there are 
very few studies which have examined MetS and CRP in relation to breast and 
colorectal mortality.  
The results of this dissertation research support the link between obesity 
and increased risk of post-menopausal breast and colorectal cancer (144). 
Hyperinsulinemia is one of the strongest established biochemical link between 
obesity and colorectal cancer (38). The link between obesity and breast cancer is 
believed to be related to endogenous estrogen, insulin resistance and 
inflammation (9, 10). Adipose tissue is a major source of estrogenic hormones 
and both aromatase expression and estrogen synthesis are linked to increased 
risk of breast cancer (94). The inflammation pathway originates in tissues 
involved in metabolism: adipose tissue, liver and muscle tissues (96). The tissue 
in response to the stimulus triggers the inflammatory response (93, 96). 
Inflammatory responses are characterized by an increase of cytokines and 
markers of active inflammation (CRP and fibrinogen). Persons who are 
overweight and obese experience low grade chronic inflammation and (96) have 
increased blood insulin levels (145) .  
In conclusion, our results confirm previous findings that early adulthood 
BMI, waist circumference and their change overtime are independently 
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associated with increased risk for advanced colorectal neoplasia. MetS and 
elevated CRP are prevalent among breast cancer survivors and has been 
associated with increased risk of breast and colorectal cancer mortality. The 
results highlight the importance of maintaining a healthy BMI throughout adult life 
for preventing advanced neoplasia as well as both colorectal and breast cancer 
mortality. Health care providers may use the findings as a prevention strategy for 
breast and colorectal cancer when counseling their patients, in line with the 
American Society of Clinical Oncology’s prioritization of educating providers and 
patients on the role of energy balance as a strategy to reduce the impact of 
obesity on cancer (67). 
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